CoreLab Partners, Inc has launched a new semi automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions (A.M.P.S.) LLC.
“We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform,” added Woehler.
The AMPS CalECG application, originally designed for the on-screen measurement of ECG signals in the context of pharmaceutical trials, is capable of handling digital ECGs, interfacing with several types of formats. The recently introduced version 3 of CalECG includes the new powerful measurement algorithm, Bravo, as well as a diagnostic module assisting the user in the determination of important caliper positions.
CoreLab Partners has also licensed the full set of AMPS Heart Rate Variability tools (WinHRV), which has been extensively used in the academic domain for the assessment of autonomic nervous systems changes associated with both clinical and drug-induced conditions.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.